secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001193125-24-000249
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero starts Phase 3 PIVOT-PO trial of tebipenem HBr; $95M milestone payable over two years from GSK
--------------------------------------------------------------------------------

- First patient first visit for Phase 3 PIVOT-PO trial (cUTI/AP) targeting ~2,648 patients.
- Primary endpoint: overall response (composite of clinical cure + microbiological eradication) at test-of-cure.
- Non-inferiority vs IV imipenem cilastatin with 10% NI margin in microbiological ITT population.
- GSK license: $95M development milestone payable in 4 equal semiannual installments over 2 years.
- Additional milestones: $25M on FDA submission, up to $150M commercial, up to $225M sales, plus tiered royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524000249/0001193125-24-000249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524000249/d360654d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-000249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer